Return to search results.
Complete title: A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung
|Research Study Number||7008|
|Principal Investigator||Robin Jones|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Bone Cancer; Sarcoma; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.